Kisspeptin
Family entry for the KISS1-derived peptides (kisspeptin-54, -14, -13 and -10) that activate KISS1R to drive hypothalamic GnRH release; the isoform-specific evidence lives on the kisspeptin-54 and kisspeptin-10 profiles.
Also referenced as: Kisspeptins, KiSS-1 peptides, KISS1 peptides
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Kisspeptin crosses your target, drops, or sets a new tracked low—without daily noise.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Kisspeptins, KiSS-1 peptides, KISS1 peptides
No FDA label signal · 45 trials · 3337 PubMed results
Kisspeptin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Kisspeptin has 31 name-matched clinical trials (7 international) (highest phase: Phase 3) and 3337 PubMed-indexed publications and is not FDA-approved. 4 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Kisspeptin?
“Kisspeptin” is not one molecule but a family of peptides cleaved from the precursor encoded by the KISS1 gene: kisspeptin-54 (also called metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10, all ending in the same C-terminal RF-amide decapeptide. The two forms with a human literature have their own profiles. Kisspeptin-54 is the major circulating isoform and the one used in most reproductive-endocrinology trials. Kisspeptin-10 is the decapeptide that research catalogs usually mean by “kisspeptin,” and the form in the current investigator trials.
How it works
Every isoform activates the same receptor, KISS1R (GPR54), on hypothalamic GnRH neurons, triggering endogenous GnRH and therefore LH and FSH release; the isoforms differ in length and pharmacokinetics, not in receptor target.
Research status
No kisspeptin product is approved anywhere; the evidence is split by isoform and summarized on each profile, and the Investigational status of this family entry mirrors the registered investigator trials of the individual isoforms.
Common dosage forms
Only research-grade lyophilized powder exists, and a vial labeled “kisspeptin” is almost always kisspeptin-10.
Key considerations
Check which isoform a listing, certificate of analysis, or citation refers to before comparing it with the published trials; kisspeptin-54 results do not transfer automatically to kisspeptin-10, and the FDA’s 503A Category 2 entry names kisspeptin-10 specifically.